Your browser is no longer supported. Please, upgrade your browser.
NKTR Nektar Therapeutics weekly Stock Chart
NKTR [NASD]
Nektar Therapeutics
Index- P/E- EPS (ttm)-2.62 Insider Own1.10% Shs Outstand177.19M Perf Week-5.12%
Market Cap3.83B Forward P/E- EPS next Y-2.43 Insider Trans-5.18% Shs Float175.90M Perf Month10.26%
Income-460.80M PEG- EPS next Q-0.69 Inst Own99.49% Short Float15.97% Perf Quarter4.28%
Sales137.00M P/S27.99 EPS this Y-166.60% Inst Trans0.68% Short Ratio20.05 Perf Half Y6.01%
Book/sh7.32 P/B2.96 EPS next Y10.80% ROA-22.90% Target Price31.43 Perf Year-32.42%
Cash/sh7.62 P/C2.85 EPS next 5Y-7.30% ROE-32.10% 52W Range13.63 - 36.85 Perf YTD0.53%
Dividend- P/FCF- EPS past 5Y-42.70% ROI-26.60% 52W High-41.11% Beta1.96
Dividend %- Quick Ratio3.70 Sales past 5Y-10.60% Gross Margin85.60% 52W Low59.21% ATR0.96
Employees723 Current Ratio3.80 Sales Q/Q79.40% Oper. Margin- RSI (14)54.21 Volatility4.20% 5.01%
OptionableYes Debt/Eq0.20 EPS Q/Q-14.80% Profit Margin- Rel Volume1.06 Prev Close22.21
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume1.40M Price21.70
Recom2.20 SMA201.59% SMA5011.48% SMA20010.02% Volume1,478,323 Change-2.30%
May-12-20Reiterated H.C. Wainwright Neutral $32 → $26
Apr-22-20Initiated The Benchmark Company Buy $26
Mar-30-20Upgrade Goldman Sell → Neutral $18 → $20
Mar-04-20Initiated Barclays Overweight $30
Feb-03-20Upgrade Mizuho Neutral → Buy $21 → $35
Oct-24-19Initiated Oppenheimer Perform $18
Oct-08-19Downgrade Goldman Buy → Sell $54 → $16
Aug-09-19Downgrade Mizuho Buy → Neutral $79 → $21
Aug-09-19Downgrade JP Morgan Overweight → Neutral $62 → $33
Aug-09-19Downgrade Jefferies Buy → Hold $59 → $23
Mar-15-19Initiated SVB Leerink Mkt Perform $38
Dec-13-18Initiated Goldman Buy $62
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Jun-04-18Reiterated H.C. Wainwright Buy $125 → $97
Apr-20-18Initiated Seaport Global Securities Buy $120
Apr-13-18Resumed Piper Jaffray Overweight $125
Apr-06-18Reiterated Mizuho Buy $89 → $103
Apr-02-18Resumed H.C. Wainwright Buy $125
Mar-02-18Reiterated Canaccord Genuity Buy $80 → $94
Jan-22-18Reiterated Mizuho Buy $45 → $89
May-29-20 05:00PM  Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020) PR Newswire
May-26-20 11:11AM  7 Stocks Maverick Capital Continues to Buy GuruFocus.com
May-22-20 08:30AM  Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal PR Newswire
May-18-20 08:05AM  Is There An Opportunity With Nektar Therapeutics's (NASDAQ:NKTR) 46% Undervaluation? Simply Wall St.
May-17-20 07:13PM  Oppenheimer Sticks to Their Hold Rating for Nektar Therapeutics Investing.com
May-12-20 06:27AM  H.C. Wainwright Sticks to Their Hold Rating for Nektar Therapeutics Investing.com
May-08-20 10:29AM  Nektar's (NKTR) Q1 Earnings and Revenues Top Estimates Zacks
04:12AM  Edited Transcript of NKTR earnings conference call or presentation 7-May-20 9:00pm GMT Thomson Reuters StreetEvents
03:57AM  No Surprises in Nektar's Q1; COVID-19 Likely Just a Small Bump in Road for Bempeg Trials Morningstar
03:31AM  Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript Motley Fool
May-07-20 05:55PM  Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:15PM  Nektar Therapeutics Reports First Quarter 2020 Financial Results PR Newswire
Apr-30-20 12:33PM  Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline Zacks
Apr-28-20 05:00PM  Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets PR Newswire
Apr-09-20 06:08PM  Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays American City Business Journals
Apr-06-20 06:24AM  Need To Know: Analysts Are Much More Bullish On Nektar Therapeutics (NASDAQ:NKTR) Revenues Simply Wall St. +7.12%
Mar-29-20 10:51PM  Hedge Funds Are Betting On Nektar Therapeutics (NKTR) Insider Monkey
Mar-28-20 11:30AM  Why Is Nektar (NKTR) Down 16.1% Since Last Earnings Report? Zacks
Mar-11-20 09:19PM  Edited Transcript of NKTR earnings conference call or presentation 27-Feb-20 10:00pm GMT Thomson Reuters StreetEvents -8.40%
Mar-01-20 09:15AM  Nektar Therapeutics Just Reported And Analysts Have Been Cutting Their Estimates Simply Wall St.
Feb-28-20 06:30PM  Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference PR Newswire
08:15AM  Nektar (NKTR) Q4 Earnings & Revenues Top Estimates, Stock Up Zacks
04:39AM  Business as Usual for No-Moat Nektar; Bempeg's Phase Three Trials With Bristol to See 2021 Readouts Morningstar
Feb-27-20 05:35PM  Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:15PM  Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results PR Newswire
Feb-20-20 12:31PM  Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-18-20 05:00PM  Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets PR Newswire
Feb-17-20 10:27AM  Lee Ainslie Buys Crown Holdings, Monster Beverage GuruFocus.com
Feb-10-20 02:56PM  Here's What We Think About Nektar Therapeutics's (NASDAQ:NKTR) CEO Pay Simply Wall St.
09:28AM  Alkermes (ALKS) to Report Q4 Earnings: What's in Store? Zacks
Feb-06-20 05:50PM  Nektar Therapeutics (NKTR) Stock Sinks As Market Gains: What You Should Know Zacks
Feb-03-20 09:12AM  US STOCKS-Wall Street set to open higher after steep selloff Reuters +8.30%
08:00AM  Nektar Therapeutics Announces Publication of Two Manuscripts on Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) in Nature Communications PR Newswire
Jan-29-20 03:46PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics  - NKTR GlobeNewswire
Jan-27-20 09:08AM  3 Biotech Stocks Nearing Support Investopedia -6.44%
Jan-24-20 07:02PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR CNW Group
Jan-23-20 11:43AM  Nektar Therapeutics Pullback May Be Short-Lived Schaeffer's Investment Research
Jan-21-20 05:53PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
Jan-16-20 01:37PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
Jan-15-20 04:08PM  How An FDA Committee Pulled The Rug Out From This Highflying Biotech Investor's Business Daily -15.99%
10:27AM  Nektar's Pain Drug Gets Adverse Advisory Committee Decision Zacks
10:23AM  Its opioid dissed by FDA advisors, S.F. drugmaker abandons program American City Business Journals
09:17AM  Benzinga Pro's Top 5 Stocks To Watch For Wed., Jan. 15, 2020: GS, RSX, NKTR, NVAX, ACB Benzinga
08:22AM  The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance Benzinga
07:30AM  Nektar Stock Plunges 15% as FDA Panel Rejects Opioid Painkiller Barrons.com
04:44AM  Nektar Squeezed as FDA Rejects Opioid Addiction-Fighting Drug TheStreet.com
Jan-14-20 10:47PM  Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol PR Newswire
06:27PM  Nektar stock drops more than 10% as FDA advisers say no to painkiller MarketWatch
10:49AM  'Unlikeable' opioid from Nektar faces FDA pain point American City Business Journals
05:00AM  Top Picks 2020- Nektar Therapeutics NKTR MoneyShow
Jan-13-20 09:14AM  Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration Zacks
Jan-10-20 04:08PM  Why Bristol's Vote Of Confidence Sent This Biotech Stock Rocketing Investor's Business Daily +24.69%
02:32PM  Shareholder Alert: Robbins LLP Reminds Investors Nektar Therapeutics (NKTR) Sued for Misleading Shareholders Business Wire
01:34PM  Nektar Therapeutics Options Pop as Stock Soars Schaeffer's Investment Research
08:01AM  Nektar Therapeutics, Bristol-Myers Expand Effort to Develop Treatment for Cancer TheStreet.com
06:59AM  Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab) Business Wire
Jan-07-20 09:00AM  Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA PR Newswire
Dec-24-19 01:09PM  Why A Bidding War For Synthorx Bodes Well For This Biotech Stock Investor's Business Daily
10:10AM  Trade Deal Optimism Fuels Santa Rally: ETFs & Stocks to Bet On Zacks
Dec-19-19 12:21PM  10 Stocks That Could Be Tax-Loss Buying Opportunities Benzinga
08:59AM  5 Losing Stocks From 2019 to Rebound Next Year Zacks
Dec-17-19 09:00AM  Nektar Therapeutics Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D. PR Newswire
Dec-10-19 07:49PM  Is Nektar Therapeutics (NKTR) A Good Stock To Buy? Insider Monkey
05:00AM  Introducing Nektar Therapeutics (NASDAQ:NKTR), A Stock That Climbed 84% In The Last Three Years Simply Wall St.
Dec-09-19 10:05AM  Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting PR Newswire +13.03%
Dec-06-19 11:31AM  Why Is Nektar (NKTR) Up 6.2% Since Last Earnings Report? Zacks
Dec-03-19 09:00AM  Nektar Appoints John Northcott as Chief Commercial Officer PR Newswire
Nov-13-19 05:30PM  Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference PR Newswire
Nov-12-19 11:11PM  Edited Transcript of NKTR earnings conference call or presentation 6-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
09:33AM  Company News For Nov 12, 2019 Zacks
Nov-11-19 04:25PM  Can This Biotech Improve On Bristol-Myers' Blockbuster Cancer Drug? Investor's Business Daily
08:55AM  Nektar Therapeutics Stock Is Rising on Test Data for Cancer Drug Barrons.com
Nov-10-19 11:00AM  Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology PR Newswire
Nov-09-19 05:30PM  Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting PR Newswire
Nov-07-19 11:13AM  Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up Zacks
Nov-06-19 06:15PM  Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:03PM  Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019 PR Newswire
Nov-03-19 10:51AM  The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight Benzinga
Nov-01-19 09:00AM  Nektar Therapeutics to Host Webcast Conference Call with Melanoma Specialist for Analysts & Investors During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting PR Newswire +6.92%
Oct-30-19 05:00PM  Nektar to Announce Financial Results for the Third Quarter 2019 on Wednesday, November 6, 2019, After Close of U.S.-Based Financial Markets PR Newswire
10:34AM  Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Oct-28-19 07:46PM  Is Nektar Therapeutics (NKTR) Going To Burn These Hedge Funds ? Insider Monkey +6.12%
Oct-25-19 06:00AM  With Good Trial Results, Nektar Therapeutics Could "Turn on a Dime" MoneyShow
Oct-23-19 03:26PM  16 Stocks With The Highest Long-Term Sales Growth Rate Benzinga
Oct-18-19 03:00PM  DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019 GlobeNewswire
10:07AM  FINAL DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019 ACCESSWIRE
Oct-17-19 01:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR ACCESSWIRE
11:18AM  KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for NEKTAR THERAPEUTICS Investors NKTR GlobeNewswire
Oct-16-19 06:03PM  FINAL DEADLINE APPROACHING: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics Business Wire
10:11AM  NKTR CLASS ACTION DEADLINE IN 1 DAY: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Nektar Therapeutics Business Wire
10:06AM  DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019 ACCESSWIRE
09:00AM  Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma PR Newswire
Oct-15-19 08:49PM  DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics, Inc. (NASDAQ: NKTR) and Encourages Nektar Investors to Contact the Firm Business Wire +8.98%
05:55PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR GlobeNewswire
05:18PM  INVESTOR DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics ACCESSWIRE
Oct-12-19 08:03AM  Does Nektar Therapeutics (NASDAQ:NKTR) Have A Healthy Balance Sheet? Simply Wall St.
06:50AM  CLASS ACTION DEADLINES: Brodsky & Smith, LLC Reminds Investors of Approaching Deadlines Related to the Following Companies: VAL, NKTR and NTAP ACCESSWIRE
Oct-11-19 06:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR ACCESSWIRE +5.95%
03:00PM  DEADLINE ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Deadline: October 18, 2019 GlobeNewswire
10:05AM  INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies of Class Action and Lead Deadline: October 18, 2019 ACCESSWIRE
Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. The company develops NKTR-181, a novel mu-opioid analgesic drug, which is in Phase III clinical trial for chronic low back pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I is designed to provide rapid activation and proliferation of cancer-killing CD8+ effector T cells and NK cells. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for oncology; and NKTR-255, which is in phase I for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Labrucherie Gil MSVP, COO & CFOMay 19Sale22.622,00045,240245,494May 20 06:29 PM
Zalevsky JonathanChief R&D OfficerMay 18Sale22.514,558102,601322,515May 20 06:33 PM
Wilson Mark AndrewSVP & General CounselMay 18Sale22.511,52934,41852,418May 20 06:32 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 18Sale22.511,36730,771172,719May 20 06:31 PM
Labrucherie Gil MSVP, COO & CFOMay 18Sale22.515,727128,915247,494May 20 06:29 PM
ROBIN HOWARD WPresident & CEOMay 18Sale22.518,968201,870375,903May 20 06:30 PM
CHESS ROBERTDirectorApr 15Sale18.388,000147,010276,973Apr 17 06:03 PM
CHESS ROBERTDirectorMar 11Sale16.798,000134,316276,973Mar 13 06:04 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 18Sale22.351,39431,156174,086Feb 20 06:39 PM
Zalevsky JonathanChief R&D OfficerFeb 18Sale22.354,774106,699327,073Feb 20 06:39 PM
Labrucherie Gil MSVP, COO & CFOFeb 18Sale22.355,938132,714253,221Feb 20 06:37 PM
ROBIN HOWARD WPresident & CEOFeb 18Sale22.358,448188,813384,871Feb 20 06:38 PM
CHESS ROBERTDirectorFeb 12Sale23.508,000188,000276,973Feb 14 07:00 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 06Option Exercise7.2137,500270,375212,980Feb 07 07:31 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 06Sale22.7837,500854,250175,480Feb 07 07:31 PM
WHITFIELD ROY ADirectorDec 18Option Exercise9.2410,00092,400198,250Dec 20 06:31 PM
Zalevsky JonathanChief R&D OfficerNov 18Sale17.973,96071,161291,697Nov 20 07:07 PM
ROBIN HOWARD WPresident & CEONov 18Sale17.9713,556243,601299,219Nov 20 07:05 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 18Sale17.972,71348,753160,441Nov 20 07:06 PM
Labrucherie Gil MSVP, COO & CFONov 18Sale17.978,863159,268219,009Nov 20 07:04 PM
Labrucherie Gil MSVP, COO & CFONov 13Option Exercise7.2125,000180,250252,872Nov 15 06:09 PM
Labrucherie Gil MSVP, COO & CFONov 13Sale19.7925,000494,750227,872Nov 15 06:09 PM
ROBIN HOWARD WPresident & CEOOct 17Option Exercise7.2133,333240,331346,108Oct 17 07:00 PM
ROBIN HOWARD WPresident & CEOOct 17Sale17.6833,333589,327312,775Oct 17 07:00 PM
ROBIN HOWARD WPresident & CEOOct 16Option Exercise7.2133,334240,338346,109Oct 17 07:00 PM
ROBIN HOWARD WPresident & CEOOct 16Sale17.4833,334582,678312,775Oct 17 07:00 PM
Labrucherie Gil MSVP, COO & CFOOct 15Option Exercise7.2125,000180,250252,872Oct 17 06:59 PM
ROBIN HOWARD WPresident & CEOOct 15Option Exercise7.2133,333240,331346,108Oct 17 07:00 PM
ROBIN HOWARD WPresident & CEOOct 15Sale16.9533,333565,085312,775Oct 17 07:00 PM
Labrucherie Gil MSVP, COO & CFOOct 15Sale15.8325,000395,750227,872Oct 17 06:59 PM
Ajer Jeffrey RobertDirectorSep 30Sale18.062,37542,89322,375Oct 01 07:16 PM
Lingnau LutzDirectorSep 27Sale17.843,00053,52026,700Oct 02 07:51 PM
CHESS ROBERTDirectorSep 27Sale17.994,00071,960276,973Oct 01 07:15 PM
Ajer Jeffrey RobertDirectorSep 20Sale20.242,25045,54018,250Sep 24 06:07 PM
Labrucherie Gil MSVP & Chief Financial OfficerSep 16Option Exercise7.2125,000180,250177,872Sep 18 07:07 PM
Labrucherie Gil MSVP & Chief Financial OfficerSep 16Sale20.5225,000513,000152,872Sep 18 07:07 PM
Doberstein Stephen KSVP & Chief Scientific OfficerSep 05Buy17.2815,000259,200107,668Sep 09 05:09 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 26Option Exercise16.3130,000489,300152,872Aug 27 05:20 PM
ROBIN HOWARD WPresident & CEOAug 23Option Exercise16.3130,000489,300312,775Aug 26 05:21 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerAug 16Sale18.151,80932,833163,154Aug 19 07:09 PM
ROBIN HOWARD WPresident & CEOAug 16Sale18.1512,551227,801282,775Aug 19 07:08 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 16Sale18.155,06391,893122,872Aug 19 07:07 PM
Nicholson JohnSVP & Chief Operating OfficerAug 16Sale18.153,81969,315162,759Aug 19 07:07 PM
Doberstein Stephen KSVP & Chief Scientific OfficerAug 16Sale18.153,24558,89792,668Aug 19 07:06 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 14Option Exercise7.2125,000180,250152,935Aug 16 08:13 PM
Labrucherie Gil MSVP & Chief Financial OfficerAug 14Sale17.7925,000444,750127,935Aug 16 08:13 PM
ROBIN HOWARD WPresident & CEOJul 25Option Exercise7.2133,333240,331328,659Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 25Sale29.6533,333988,323295,326Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 24Option Exercise7.2133,334240,338328,660Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 24Sale32.1133,3341,070,355295,326Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 23Option Exercise7.2133,333240,331328,659Jul 25 08:02 PM
ROBIN HOWARD WPresident & CEOJul 23Sale32.1033,3331,069,989295,326Jul 25 08:02 PM
Labrucherie Gil MSVP & Chief Financial OfficerJul 10Option Exercise7.2125,000180,250152,935Jul 12 06:31 PM
Labrucherie Gil MSVP & Chief Financial OfficerJul 10Sale34.5725,000864,250127,935Jul 12 06:31 PM
Lingnau LutzDirectorJul 08Option Exercise9.2410,00092,40033,200Jul 10 05:34 PM
Lingnau LutzDirectorJul 08Sale34.6310,000346,30023,200Jul 10 05:34 PM
Labrucherie Gil MSVP & Chief Financial OfficerJun 17Option Exercise7.2125,000180,250152,935Jun 19 05:50 PM
Labrucherie Gil MSVP & Chief Financial OfficerJun 17Sale33.7125,000842,750127,935Jun 19 05:50 PM